View Study [2]"Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide" Enebo LB et al., 2021 Finding: Phase 1b trial demonstrated that combining cagrilintide with semaglutide 2.4mg resulted in up to 17.1% weight loss at 20 weeks, with the combination being well-tolerated
Most therapeutic compounds target a single pathway, but this peptide orchestrates a coordinated biological response through at least six distinct molecular routes
Atkinson JP, McGinnis K, Shreffler D (1980) Development and characterization of a hemolytic assay for mouse C4
PhaseOne also supplies GLOW, which extends this combination to include GHK-Cu for its copper-dependent mechanism, and KLOW, which adds KPV as a fourth component
doi: 10.1023/a:1025493705728